Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Clin Cancer Res
.
2022 Jan 15;28(2):429.
doi: 10.1158/1078-0432.CCR-21-4241.
Authors
Mansoor N Saleh
,
Manish R Patel
,
Todd M Bauer
,
Sanjay Goel
,
Gerald S Falchook
,
Geoffrey I Shapiro
,
Ki Y Chung
,
Jeffrey R Infante
,
Robert M Conry
,
Guilherme Rabinowits
,
David S Hong
,
Judy S Wang
,
Ulrich Steidl
,
Loren D Walensky
,
Gurudatta Naik
,
Vincent Guerlavais
,
Vojislav Vukovic
,
D Allen Annis
,
Manuel Aivado
,
Funda Meric-Bernstam
PMID:
35045962
PMCID:
PMC10361214
DOI:
10.1158/1078-0432.CCR-21-4241
No abstract available
Publication types
Published Erratum